Anti-CD157 Antibody CDR Optimization for Specific Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-CD157 antibodies and associated methods are limited in their range of both in vitro and in vivo applications, particularly in terms of target specificity and efficacy.
Innovation Solution
Development of antibodies and antigen-binding fragments with specific CDR sequences that enhance binding affinity and specificity to CD157, including humanized antibodies with optimized CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 regions, enabling superior target specificity and signal-to-noise ratios.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If currently available anti-CD157 antibodies are used, then basic binding function is achieved, but target specificity and efficacy are limited
Solution Approach 1:
The patent applies parameter changes by optimizing the amino acid sequences of complementarity determining regions (CDRs) in the antibody variable regions. Specific substitutions in CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 regions are made to enhance binding affinity and specificity to CD157, directly resolving the contradiction between measurement precision (target specificity) and reliability (efficacy)
Solution Approach 2:
The patent applies local quality by making targeted amino acid substitutions specifically in the CDR regions of the antibody variable domains while maintaining the overall antibody structure. This localized optimization of binding regions improves target specificity without compromising overall antibody function and efficacy
2Measurement precision
If antibody sequences are optimized for binding affinity, then target specificity improves, but signal-to-noise ratio may be compromised
Solution Approach 1:
The patent simultaneously optimizes multiple CDR region parameters to achieve both high target specificity and improved signal-to-noise ratio. The coordinated substitutions across CDRH1-3 and CDRL1-3 regions enhance affinity for CD157 while reducing non-specific binding, thereby improving the signal-to-noise ratio alongside target specificity
Data Source
AI summary
Compositions and methods for making and using anti-CD157 antibodies or antigen-binding fragments thereof, for example, monoclonal antibodies, CD157-binding antibody fragments, and derivatives are described, as are nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-CD157 antibodies or antigen-binding fragments thereof, and methods of making and using the same.